太龙药业控股股东筹划股份转让事宜 股票继续停牌

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) announced that its controlling shareholder, Tai Rong Chan Investment, is planning a share transfer that may lead to a change in the company's control [1] Group 1 - The company received a notification from its controlling shareholder on December 1, 2025, regarding the share transfer [1] - The company's stock was suspended from trading starting December 2, 2025, due to this significant matter [1] - The controlling shareholder is actively negotiating the terms of the transaction and is undergoing necessary internal approval processes [1] Group 2 - The company anticipates that it will not be able to resume trading on December 4, 2025, as initially expected [1] - An application has been submitted to the Shanghai Stock Exchange for continued suspension of trading, which is expected to last no more than three trading days [1]